Peroxisome Proliferator-Activated Receptor-γ in Amyotrophic Lateral Sclerosis and Huntington's Disease
2008
PPAR-γ in ALS and Huntington's Disease
publication
Evidence: moderate
Author Information
Author(s): Kiaei Mahmoud
Primary Institution: Weill Medical College of Cornell University
Hypothesis
Can PPAR-γ agonists provide neuroprotection in ALS and Huntington's disease?
Conclusion
PPAR-γ agonists like pioglitazone may improve survival and reduce neuroinflammation in ALS models.
Supporting Evidence
- Pioglitazone treatment improved motor performance and delayed weight loss in ALS mice.
- PPAR-γ agonists have shown neuroprotective effects in various experimental models.
- Neuroinflammation is a common feature in ALS, and PPAR-γ may help regulate it.
Takeaway
This study suggests that a drug called pioglitazone might help people with ALS by protecting their brain cells from damage.
Methodology
The effects of pioglitazone were tested in a transgenic mouse model of ALS.
Limitations
The role of PPAR-γ in Huntington's disease remains unclear as one study showed no beneficial effects.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website